Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026
Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026
Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026
Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 23, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.2K

Study May Change Approach to Immunotherapy

    Cancer Discovery
    |March 26, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Patients with more clonal neoantigens than subclonal neoantigens in tumors show better response to immunotherapy. This finding could guide checkpoint inhibitor use and vaccine development for cancer treatment.

    More Related Videos

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.2K
    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    10.7K

    Related Experiment Videos

    Last Updated: Mar 23, 2026

    Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
    12:19

    Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

    Published on: June 7, 2024

    2.2K
    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.2K
    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    10.7K

    Area of Science:

    • Oncology
    • Immunology
    • Computational Biology

    Background:

    • Immunotherapy has revolutionized cancer treatment by harnessing the patient's immune system.
    • Neoantigens, unique tumor-specific antigens, are crucial targets for anti-cancer immune responses.
    • Distinguishing between clonal and subclonal neoantigens is critical for predicting treatment efficacy.

    Discussion:

    • This study highlights the differential impact of clonal versus subclonal neoantigens on immunotherapy response.
    • Tumor neoantigen landscape heterogeneity influences patient outcomes.
    • Understanding neoantigen prevalence is key to personalized cancer medicine.

    Key Insights:

    • A higher proportion of clonal neoantigens strongly correlates with positive responses to immunotherapy.
    • Subclonal neoantigens may represent less effective targets for current immunotherapeutic strategies.
    • This predictive biomarker can refine patient selection for immunotherapy.

    Outlook:

    • Findings may inform the clinical application of immune checkpoint inhibitors.
    • Potential for developing novel neoantigen-based cancer vaccines.
    • Future research could explore therapeutic strategies targeting subclonal neoantigens.